Results 11 to 20 of about 7,321 (205)

Clinical use, efficacy, and durability of maraviroc for antiretroviral therapy in routine care: A European survey. [PDF]

PLoS ONE, 2019
ObjectivesThe study aimed to survey maraviroc use and assess effectiveness and durability of maraviroc-containing antiretroviral treatment (ART) in routine practice across Europe.MethodsData were retrieved from 26 cohorts in 8 countries comprising adults
Andrea De Luca, Patrizio Pezzotti, Charles Boucher, Matthias Döring, Francesca Incardona, Rolf Kaiser, Thomas Lengauer, Nico Pfeifer, Eugen Schülter, Anne-Mieke Vandamme, Maurizio Zazzi, Anna Maria Geretti, EucoHIV Study Group   +12 more
doaj   +3 more sources

Pharmacokinetics and safety of maraviroc in neonates [PDF]

AIDS, 2020
Objective: The aim of this study was to evaluate safety and pharmacokinetics of maraviroc administered with standard antiretroviral prophylaxis to HIV-1 exposed infants and to determine the appropriate dose of maraviroc during the first 6 weeks of life.
Rosebush, Julia C, Best, Brookie M, Chadwick, Ellen G, Butler, Kevin, Moye, John, Smith, Elizabeth, Bradford, Sarah, Reding, Christina A, Mathiba, Sisinyana R, Hanley, Sherika, Aziz, Mariam, Homans, James, Acosta, Edward P, Murtaugh, William, Vourvahis, Manoli, Mcfadyen, Lynn, Hayward, Katy, Mirochnick, Mark, Samson, Pearl   +18 more
openaire   +6 more sources

Short-term maraviroc exposure, a clinical approach to decide on maraviroc prescription in HIV-1-infected treatment-naïve patients

Drug Design, Development and Therapy, 2016
Alejandro Gonzalez-Serna,1 Miguel Genebat,2 Ezequiel Ruiz-Mateos,2 Manuel Leal2 1Laboratory of Molecular Immunobiology, Hospital General Universitario Gregorio Maranon, Madrid, 2Laboratory of Immunovirology, Institute of Biomedicine of Seville, Seville,
Gonzalez-Serna A, Genebat M, Ruiz-Mateos E, Leal M   +3 more
doaj   +1 more source

Maraviroc attenuates trauma-hemorrhage-induced hepatic injury through PPAR gamma-dependent pathway in rats.

PLoS ONE, 2013
Maraviroc is a CC-chemokine receptor 5 (CCR5) antagonist with potent antiviral and cancer preventive effects. Recent evidence suggests that the co-existence of CCR5 in various cell types is involved in inflammation.
Fu-Chao Liu, Yung-Fong Tsai, Huang-Ping Yu   +2 more
doaj   +2 more sources

Profile of maraviroc: a CCR5 antagonist in the management of treatment-experienced HIV patients

HIV/AIDS: Research and Palliative Care, 2010
Thore LorenzenIFI Institute for Interdisciplinary Medicine, Hamburg, GermanyAbstract: Maraviroc is the first and, so far, the only licensed representative of the class of chemokine receptor type 5 (CCR5) inhibitors used for the treatment of human ...
Thore Lorenzen
doaj   +1 more source

Neurocognition with maraviroc compared with tenofovir in HIV [PDF]

AIDS, 2016
To determine whether maraviroc (MVC) has unique neurocognitive benefits in the context of initial antiretroviral therapy (ART).
Kevin R, Robertson, Sachiko, Miyahara, Anthony, Lee, Todd T, Brown, Ellen S, Chan, Baiba, Berzins, David, Rusin, Joseph J, Eron, Babafemi O, Taiwo   +8 more
openaire   +4 more sources

Loss of SOCS1 in Donor T Cells Exacerbates Intestinal GVHD by Driving a Chemokine-Dependent Pro-Inflammatory Immune Microenvironment. [PDF]

Adv Sci (Weinh)
T cell‐specific Socs1 knockout leads to inflammatory differentiation of CD8+ T cells, prompting the STAT1/2 complex to drive the activation of Ccl5, Ccr5, and Cxcr3, and promoting the skewing of monocytes toward a pro‐inflammatory M1 macrophage lineage.
Wu Z, Wang B, Jiang X, Zhang F, Huang Q, Wu X, Fan S, Zhang Q, Zhou J, Tang J, Mo XD, Wang Y, Chang YJ, Guo H, Huang XJ.   +14 more
europepmc   +2 more sources

Maraviroc Population Pharmacokinetics Within the First 6 Weeks of Life [PDF]

, 2022
BACKGROUND: Treatment and prophylaxis options for neonatal HIV are limited. This study aimed to develop a population pharmacokinetic model to characterize the disposition of maraviroc in neonates to inform dosing regimens and expand available options ...
Mark Mirochnick, Patrick Jean-Philippe, Best, Brookie M, Marlon Liyanage, Liyanage, Marlon, Nikanjam, Mina, McFadyen, Lynn, Lynn McFadyen, Capparelli, Edmund V, Mirochnick, Mark, Bradford, Sarah, Ellen G. Chadwick, Whitson, Kyle, Sarah Bradford, Kyle Whitson, John Moye, Rogg, Luise, Moye, John, Brookie M. Best, Luise Rogg, Chadwick, Ellen G, Edmund V. Capparelli, Vourvahis, Manoli, Manoli Vourvahis, Mina Nikanjam, Jean-Philippe, Patrick   +25 more
core   +1 more source

Adverse Reactions (AR) to maraviroc.

, 2023
ObjectivesMaraviroc may reduce hepatic inflammation in people with HIV and non-alcoholic fatty liver disease (HIV-NAFLD) through CCR5-receptor antagonism, which warrants further exploration.MethodsWe performed an open-label 96-week randomised-controlled ...
Mark Nelson (213425), Iga Abramowicz (10587491), Rosalie Housman (16548559), Yvonne Gilleece (10353449), Chloe Orkin (254460), Emily Clarke (11302620), Sarah Kirk (3739426), Sumita Verma (5566916), Louise Jennings (16548568), Nicky Perry (470939), Mark Gompels (301046), Rachel Robinson (145845), Stephen Bremner (119242), Helena Miras (16548562), Michael Curnock (16548565), Ashini Fox (731673), Daniel Bradshaw (3095049), Pauline Lambert (16548571), David Chadwick (300132)   +18 more
core   +1 more source

Immune non-response despite effective antiretroviral therapy in people living with HIV: A review of potential mechanisms, biomarkers and therapeutic approaches. [PDF]

HIV Med
Abstract Introduction A proportion of people living with HIV (PLWH) fail to restore their CD4 count or their CD4/CD8 ratio despite effective antiretroviral therapy (ART). PLWH with immune non‐response (INR) are at a higher risk of both AIDS and non‐AIDS events. The underlying mechanisms of INR remain unclear.
Silvestre C, Gross A, Makinson A.
europepmc   +2 more sources